A prospective feasibility study evaluating the implementation of model-informed precision dosing in critically ill...

Area of Science:

• Pediatric critical care medicine
• Pharmacokinetics and pharmacodynamics
• Clinical pharmacology

Background:

• Optimal antibiotic exposure is challenging in critically ill children due to physiological variability.
• Conventional dosing often fails to achieve therapeutic targets for narrow therapeutic index antibiotics like vancomycin and amikacin.

Purpose of the Study:

• To evaluate the feasibility and methodological performance of Model-Informed Precision Dosing (MIPD) in a pediatric intensive care unit.
• To compare MIPD-guided dosing with standard-of-care (SoC) for vancomycin and amikacin in critically ill children.

Main Methods:

• Prospective, pragmatic feasibility study with a comparator arm.
• Observational analysis of pediatric patients receiving vancomycin or amikacin, managed with either MIPD or SoC.
• Primary outcomes: prediction accuracy and model fit; Secondary outcomes: dose optimization, inflammatory markers, renal safety, treatment duration, and mortality.

Main Results:

• Model fit showed modest improvement for vancomycin with MIPD, while remaining unchanged in the SoC group.
• Clinical outcomes were similar between groups; however, the MIPD group showed numerically greater, though nonsignificant, reductions in CRP and procalcitonin.
• Baseline imbalances in inflammatory markers confounded interpretation of clinical outcomes.

Conclusions:

• MIPD is a potentially valuable approach for optimizing antibiotic exposure in pediatric intensive care.
• Further multicenter trials are necessary to confirm clinical benefits and optimize MIPD implementation in this population.